Quarterly ResultMay 14, 2026, 07:03 AM
Invivyd Q1 Revenue $13.7M, +22%; VYD2311 Trial Progresses
AI Summary
Invivyd reported Q1 2026 net product revenue of $13.7 million for PEMGARDA, a 22% increase year-over-year. The company posted a net loss of $41.4 million, primarily due to increased R&D costs for the VYD2311 DECLARATION pivotal program. Positive clinical developments include an IDMC recommendation to reduce VYD2311 post-dose monitoring time and the DECLARATION trial upsizing, with top-line data expected in Q3 2026. Invivyd also expanded its pipeline with measles and RSV antibody candidates.
Key Highlights
- PEMGARDA Q1 2026 net product revenue grew 22% to $13.7 million.
- Q1 2026 net loss was $41.4 million, compared to $16.3 million in Q1 2025.
- Cash and cash equivalents totaled $184.2 million as of March 31, 2026.
- Raised an additional ~$20 million gross proceeds from ATM offering in April 2026.
- R&D expenses increased to $30.7 million in Q1 2026 from $10.6 million in Q1 2025.
- IDMC recommended reducing VYD2311 post-dose monitoring time to 30 minutes.
- DECLARATION trial upsizing by ~500 subjects; top-line data expected Q3 2026.
- Advanced measles (VMS063) and RSV (VBY329) monoclonal antibody candidates.